A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)
Primary Purpose
Hepatitis E
Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Recombinant Hepatitis E Vaccine (Escherichia Coli)
Recombinant Hepatitis E Vaccine (Escherichia Coli)
Sponsored by
About this trial
This is an interventional prevention trial for Hepatitis E focused on measuring Hepatitis E
Eligibility Criteria
Inclusion Criteria:
- Aged over 18 years old on the day of enrollment, including 18 years old;
- Axillary temperature is below than 37.0 ℃;
- Negative serological markers for hepatitis E and liver function are normal or no clinical significance;
- Judged as healthy and eligible for vaccination by the investigators through a selfreported medical history and some physical examinations;
- Able to understand this study information and willing to comply with all study requirements;
- Willing to participate in this study and sign informed consent form.
Exclusion Criteria:
- Pregnancy,breast-feeding or plan to be pregnant in 7 months;
- Administration of Hepatitis E Vaccine before the study;
- Participate in any other clinical trial during the study period;
- Use of any investigational product or non-registered product (drug or vaccine)within 30 days preceding the first dose of the study vaccine or plan to use during the study period;
- Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment;
- Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine,or plan to use during the study period;
- Administration of any inactivated vaccines within 14 days preceding the first dose of the study or attenuated live vaccines within 21 days preceding the first dose of the study;
- Had a fever (axillary temperature over 38°C) within 3 days or acute illness, or use systemic antibiotics or antiviral treatment within 5 days before vaccination;
- Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor, or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response), liver and kidney disease and other chronic disease history;
- History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy,urticaria, dyspnea, angioneurotic edema or abdominal pain. Allergic history to any component of this vaccine.
- Asthma that needed emergency treatment, hospitalization, oral or intravenous corticosteroid to keep stable in the past two years;
- Combining another severe internal medicine disease(such as cardiopathy,diabetes and hyperthyroidism)
- Anormal coagulation function or coagulopathy diagnosed by doctor;
- Epilepsy(not including alcohol epilepsy within 3 years prior to abstinence and simple epilepsy that do without curing within 3 years prior to the study )
- Anomal psychology or mind affecting the individual's ability to obey the study requirement;
- Other medical, psychological, social or occupational factors that, according to the investigators' judgment,might affect the individual's ability to obey the protocol or sign the informed consent.
Sites / Locations
- Changshan Center for Disease Control and Prevention
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
the Accelerated Vaccination Schedule Group
the Standard Vaccination Schedule Group
Arm Description
Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Outcomes
Primary Outcome Measures
Anti-HEV antibody of Experimental Group
Measure anti-HEV antibody in serum samples at 51st day to evaluate the immunogenicity of the Hepatitis E vaccine.
Secondary Outcome Measures
Adverse reactions/events of Experimental Group and Control Group
Measure solicited local adverse reactions/events within 7 days after each vaccination; Measure solicited systematic adverse reactions/events within 7 days after each vaccination; Measure unsolicited adverse reactions/events within 30 days after vaccination; Measure serious adverse events occurred throughout the study(up to 7 months).
Anti-HEV antibody of Experimental Group
Measure anti-HEV antibody in serum samples at 21st day,28st day and month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.
Anti-HEV antibody of Control Group
Measure anti-HEV antibody in serum samples at month 1,2,7 to evaluate the immunogenicity of the Hepatitis E vaccine.
Full Information
NCT ID
NCT03168412
First Posted
May 14, 2017
Last Updated
February 19, 2019
Sponsor
Xiamen Innovax Biotech Co., Ltd
1. Study Identification
Unique Protocol Identification Number
NCT03168412
Brief Title
A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)
Official Title
A Study on Immunogenicity of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® Using Accelerated Vaccination Schedule in Adults (Aged Over 18 Years)
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
May 25, 2017 (Actual)
Primary Completion Date
July 15, 2018 (Actual)
Study Completion Date
November 28, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Xiamen Innovax Biotech Co., Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This phase IV clinical study was designed to evaluate the immunogenicity and safety of the recombinant Hepatitis E vaccine (Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults (over 18 years) with accelerated vaccination schedule. The study volunteers will receive the 3 doses of Hecolin® administered intramuscularly according to a 0-7-21 days schedule or a 0-1-6 month schedule.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis E
Keywords
Hepatitis E
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
125 (Actual)
8. Arms, Groups, and Interventions
Arm Title
the Accelerated Vaccination Schedule Group
Arm Type
Experimental
Arm Description
Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
Arm Title
the Standard Vaccination Schedule Group
Arm Type
Active Comparator
Arm Description
Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
Intervention Type
Biological
Intervention Name(s)
Recombinant Hepatitis E Vaccine (Escherichia Coli)
Other Intervention Name(s)
Hecolin®
Intervention Description
Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
Intervention Type
Biological
Intervention Name(s)
Recombinant Hepatitis E Vaccine (Escherichia Coli)
Other Intervention Name(s)
Hecolin®
Intervention Description
Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
Primary Outcome Measure Information:
Title
Anti-HEV antibody of Experimental Group
Description
Measure anti-HEV antibody in serum samples at 51st day to evaluate the immunogenicity of the Hepatitis E vaccine.
Time Frame
up to 2 months
Secondary Outcome Measure Information:
Title
Adverse reactions/events of Experimental Group and Control Group
Description
Measure solicited local adverse reactions/events within 7 days after each vaccination; Measure solicited systematic adverse reactions/events within 7 days after each vaccination; Measure unsolicited adverse reactions/events within 30 days after vaccination; Measure serious adverse events occurred throughout the study(up to 7 months).
Time Frame
up to 7 months
Title
Anti-HEV antibody of Experimental Group
Description
Measure anti-HEV antibody in serum samples at 21st day,28st day and month 7 to evaluate the immunogenicity of the Hepatitis E vaccine.
Time Frame
up to 7 months
Title
Anti-HEV antibody of Control Group
Description
Measure anti-HEV antibody in serum samples at month 1,2,7 to evaluate the immunogenicity of the Hepatitis E vaccine.
Time Frame
up to 7 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Aged over 18 years old on the day of enrollment, including 18 years old;
Axillary temperature is below than 37.0 ℃;
Negative serological markers for hepatitis E and liver function are normal or no clinical significance;
Judged as healthy and eligible for vaccination by the investigators through a selfreported medical history and some physical examinations;
Able to understand this study information and willing to comply with all study requirements;
Willing to participate in this study and sign informed consent form.
Exclusion Criteria:
Pregnancy,breast-feeding or plan to be pregnant in 7 months;
Administration of Hepatitis E Vaccine before the study;
Participate in any other clinical trial during the study period;
Use of any investigational product or non-registered product (drug or vaccine)within 30 days preceding the first dose of the study vaccine or plan to use during the study period;
Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy for more than 14 days in the 6 months before entry, except local treatment;
Administration of any immunoglobulin or blood products within 3 months preceding the first dose of the study vaccine,or plan to use during the study period;
Administration of any inactivated vaccines within 14 days preceding the first dose of the study or attenuated live vaccines within 21 days preceding the first dose of the study;
Had a fever (axillary temperature over 38°C) within 3 days or acute illness, or use systemic antibiotics or antiviral treatment within 5 days before vaccination;
Immunodeficiency (such as HIV carriers), primary disease of important organs, malignant tumor, or any immune disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or functional asplenia or other disease which might affect immune response), liver and kidney disease and other chronic disease history;
History of allergic disease or history of serious adverse events occurring after vaccination, i.e., allergy,urticaria, dyspnea, angioneurotic edema or abdominal pain. Allergic history to any component of this vaccine.
Asthma that needed emergency treatment, hospitalization, oral or intravenous corticosteroid to keep stable in the past two years;
Combining another severe internal medicine disease(such as cardiopathy,diabetes and hyperthyroidism)
Anormal coagulation function or coagulopathy diagnosed by doctor;
Epilepsy(not including alcohol epilepsy within 3 years prior to abstinence and simple epilepsy that do without curing within 3 years prior to the study )
Anomal psychology or mind affecting the individual's ability to obey the study requirement;
Other medical, psychological, social or occupational factors that, according to the investigators' judgment,might affect the individual's ability to obey the protocol or sign the informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhiping Chen
Organizational Affiliation
Zhejiang Provincial Center for Disease Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
Changshan Center for Disease Control and Prevention
City
Quzhou
State/Province
Zhejiang
ZIP/Postal Code
324200
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30711651
Citation
Chen Z, Lin S, Duan J, Luo Y, Wang S, Gan Z, Yi H, Wu T, Huang S, Zhang Q, Lv H. Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial. Clin Microbiol Infect. 2019 Sep;25(9):1133-1139. doi: 10.1016/j.cmi.2019.01.015. Epub 2019 Jan 31.
Results Reference
derived
Learn more about this trial
A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)
We'll reach out to this number within 24 hrs